Keep up-to-date with BMS Canada
MONTREAL April 30, 2015
MONTREAL, QUEBEC – April 29, 2015
HEPATITIS C CURE RATE OF 94% ACHIEVED IN PATIENTS POST-LIVER TRANSPLANT AND UP TO 94% IN THOSE WITH ADVANCED CIRRHOSIS (CHILD-PUGH CLASS A AND B) FOLLOWING 12-WEEK, ORAL TREATMENT WITH COMBINATION DACLATASVIR AND SOFOSBUVIR ONCE DAILY, PLUS RIBAVIRIN, IN ALLY-1 TRIALPositive results seen in historically difficult-to-treat patients without changing other medications, including those post-transplant with genotypes 1 and 3
Categories: Hepatitis C
Montreal and Toronto, April 16, 2015
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.